Stryker (WKN: 864952) SYK

Corporate Profile


Stryker is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world.

http://phx.corporate-ir.net/phoenix.zhtml?c=118965&p=irol-irhome


http://de.4-traders.com/STRYKER-CORPORATION-14536/...ide&mots=SYK

http://seekingalpha.com/symbol/SYK  

Stryker Corp. Q1 Earnings Rise 10%


Stryker Corp. (SYK) released a profit for its first quarter that rose from last year.

The company said its bottom line climbed to $468 million, or $1.24 per share. This was higher than $424 million, or $1.11 per share, in last year's first quarter.

Analysts had expected the company to earn $1.20 per share, according figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company said revenue for the quarter rose 5.0% to $2.50 billion. This was up from $2.38 billion last year.

Stryker Corp. earnings at a glance:

-Earnings (Q1): $468 Mln. vs. $424 Mln. last year. -Earnings Growth (Y-o-Y): 10.4% -EPS (Q1): $1.24 vs. $1.11 last year. -EPS Growth (Y-o-Y): 11.7% -Analysts Estimate: $1.20 -Revenue (Q1): $2.50 Bln vs. $2.38 Bln last year. -Revenue Change (Y-o-Y): 5.0%

-Guidance: Full year EPS guidance: $5.65 - $5.80

Quelle: dpa-AFX  

http://marketrealist.com/2016/11/...test-recommendations-for-stryker/  

http://finance.yahoo.com/news/...-2017-annual-dividend-193201839.html

Stryker increases 2017 annual dividend by 12% and declares a $0.425 per share quarterly dividend  

http://www.4-traders.com/...ryker-beats-4Q-profit-forecasts-23747536/

Stryker : beats 4Q profit forecasts

01/24/2017 | 04:18pm EST

KALAMAZOO, Mich. (AP) _ Stryker Corp. (SYK) on Tuesday reported fourth-quarter profit of $510 million.
The Kalamazoo, Michigan-based company said it had net income of $1.34 per share. Earnings, adjusted for amortization costs and non-recurring costs, came to $1.78 per share.
The results beat Wall Street expectations. The average estimate of 15 analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.
The medical device maker posted revenue of $3.16 billion in the period, matching Street forecasts.
For the year, the company reported profit of $1.65 billion, or $4.35 per share. Revenue was reported as $11.33 billion.
For the current quarter ending in April, Stryker expects its per-share earnings to range from $1.40 to $1.45. Analysts surveyed by Zacks had forecast adjusted earnings per share of $1.43.
The company expects full-year earnings in the range of $6.35 to $6.45 per share.
Stryker shares have risen slightly more than 1 percent since the beginning of the year, while the Standard & Poor's 500 index has risen nearly 2 percent. In the final minutes of trading on Tuesday, shares hit $121.50, a rise of 29 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SYK at https://www.zacks.com/ap/SYK
Keywords: Stryker, Earnings Report
Automated Insights, source Associated Press News  

http://www.4-traders.com/...orts-first-quarter-2017-results-24264401/  

http://www.4-traders.com/...ryker-beats-Street-2Q-forecasts-24836589/  

Stryker Corp. stock drops 4% on voluntary recall, temporary ship hold and lowered 2017 earnings guidance

http://www.marketwatch.com/story/...2017-earnings-guidance-2017-08-23  

http://www.4-traders.com/...tryker-tops-Street-3Q-forecasts-25373122/  

http://www.4-traders.com/...et-Expectations-Earnings-Review-25899328/  

http://www.4-traders.com/...ws/Stryker-1Q-Earnings-Snapshot-26440118/  

http://www.4-traders.com/...ach-to-Boston-Scientific-Update-26749703/  

http://www.4-traders.com/...s-With-Boston-Scientific-Update-26762853/  

diesmal K2M - kennt einer diese Firma genauer ? Offenbar stellen sie Produkte für die
Behandlung von Wirbelsäulenerkrankungen her.
Da es ein kleinerer Zukauf ist,  scheint es dem Kurs vorerst "egal" zu sein.  

https://www.marketscreener.com/...yker-3Q-Earnings-Snapshot-27487980/

https://www.investors.com/news/technology/...d-third-quarter-results/  

https://www.marketscreener.com/...yker-4Q-Earnings-Snapshot-27934033/

https://www.marketscreener.com/...-results-and-2019-outlook-27933733/  

siehe
https://seekingalpha.com/news/3427224-stryker-q4-top-line-9-percent

Besonders fällt die Neurotech & Spine - Sparte mit fast 20 % Umsatzwachstum auf.  

https://www.marketscreener.com/...yker-1Q-Earnings-Snapshot-28466105/  

kaufen und liegen lassen. Künstliche Knie- und Hüftgelenke sind angesichts der Demographie und der Probleme mit Überfettung der Bevölkerung in der westlichen Welt eine sichere Wette. Klingt zwar krass, aber das ist eben die Entwicklung ... muss man ja nicht gut finden. Die Aktie hat aber damit Erfolg  

zu Stryker Stryker inkl. ausführlicher Analyse

Video: https://youtu.be/jHyXGBsVFS4

Artikel: https://modernvalueinvesting.de/stryker-corp-aktienanalyse/

 

https://www.marketscreener.com/...yker-3Q-Earnings-Snapshot-29477181/  

https://www.reuters.com/article/...right-medical-buyout-idUSKBN1XE17N

(Reuters) - Medical device maker Stryker Corp (SYK.N) said on Monday it would buy smaller rival Wright Medical Group (WMGI.O) for about $4 billion in cash, expanding into the fast-growing business of implants for shoulders and wrists.  

und für 2020 werden Umsätze von ca. 1 Mrd Dollar geschätzt , was dann etwa ein Umsatz-Multiple von 4 wäre beim Kauf.  Und Stryker kann eigentlich M&A  ganz gut, ich vertraue mal darauf das sie auch hier die Integration gut hinbekommen.  

wie schätzt ihr die aktuelle Bewertung von Stryker ein?

Quick und dirty-> verglichen mit einem hist. KGV (abzgl. Extrema) von 33 scheinen zu erwartende 26 für 2019 recht fair.

Was mich allerding in der Bilanz stört, durch die vielen Übernahmen in den letzten Jahren ist das Fremdkapital deutlich gestiegen und der Goodwill in Bilanz mächtig auf 12,7Mrd USD aufgebläht.

 

Vorher waren es 0.52 $, demnach ca. +11,06 %. Zahlungstermin ist der 31.01. dann.